Company intelligence / Profile preview

Exponential Biotherapies, Inc.

New York, New York, United Statesexpobio.com ↗

Ownership: Private
Development stage: Phase 3

Overview

EBI’s lead product, a synthetic peptide derived from the human pregnancy hormone, has demonstrated positive results in Phase II clinical trials for reducing postoperative complications and is currently in Phase III studies. The therapy targets surgical stress and microvascular barrier dysfunction to reduce hospital length-of-stay and improve recovery. Additional indications are being explored for acute systemic inflammation and tissue injury post-radiation.

Therapeutic areas: OncologyImmunologyOtherNephrologyInfectious Diseases
Modalities: Synthetic peptides (polypeptides derived from human pregnancy hormone)
Industry: Biotech

Drug pipeline

1 asset

EA-230

Partnerships

Collaborations with Radboud University Medical Centre NijmegenScientific Advisory Board includes academic expertsNo major pharma partnerships disclosed publicly as of now.

Beyond the preview

Go deeper on Exponential Biotherapies, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Exponential Biotherapies, Inc..

Explore the full profile